Biological
CDP6038
CDP6038 is a biological therapy with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_1
3
75%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate
NCT01009242
completedphase_2
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
NCT01242488
completedphase_1
The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males
NCT01276119
completedphase_1
Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects
NCT01262794
Clinical Trials (4)
Showing 4 of 4 trials
NCT01009242Phase 1
To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate
NCT01242488Phase 2
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
NCT01276119Phase 1
The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males
NCT01262794Phase 1
Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4